sales projection by management, page-16

Solagran plans to increase production capacity to
200kg per year following Ropren’s entry into the
Russian Pharmacopoeia, with the required plant
upgrade requiring expenditure of around $0.75m to
$1.0m. This upgrade will allow for at least 50,000
patients to be treated per annum. The company has
also been working on options to expand capacity
beyond 200kg per year in anticipation of much greater
demand in the next 2-3 years;

So that's about 60,000 courses per year at say $2000 AU is $120 mill in sales of Ropren....80% of which is pure profit...about $100 mill.....not bad if you ask me! and doesn't even include Bio-A and Bio-B.